It can be proposed that the observed activation of the SOX2 TF is determined to a greater extent through the post-translational modifications of the SOX2 protein and/or its interaction with other factors, rather than through its level of mRNA in glioma cells. This evidence concerns the gene SOX2 and central nervous system cancer.